For treatment of Major Depressive Disorder
Suven Life Sciences announced that the first patient has been randomized in its Phase-2b clinical trial evaluating Ropanicant, a novel oral α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of Major Depressive Disorder (MDD).
The Phase-2b double blinded, placebo controlled study builds on the positive results of the completed Phase-2a trial, which demonstrated favorable safety, clinically meaningful and significant improvement in depressive symptoms from baseline based on the Montgomery berg Depression Rating Scale (MADRS) score, with indication of rapid onset of action in MDD patients distinguishing Ropanicant from existing standard therapies. Insights from Phase-2a evolved the study design, dose selection, and dosing regimen for the current Phase 2b trial being conducted in exclusively in USA under FDA IND.
"Randomizing the first patient in our Phase-2b study of Ropanicant is an important milestone for Suven Life Sciences. It reflects our continued commitment to developing innovative treatments for patients suffering from MDD. said Venkat Jasti, Chairman and MD of Suven Life Sciences.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
